PET and [18F]-FDG in oncology: A clinical update

Nuclear Medicine and Biology

Volumn 23, Issue 6, 1996, Pages 717-735

  Conti, Peter S ^a,b   Lilien, David L ^a,c   Hawley, Kimberly ^a   Keppler, Jennifer ^a   Grafton, Scott T ^a   Bading, James R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FDG; oncology; positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE;

BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; METASTASIS; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; NEOPLASM; REVIEW; SCINTISCANNING;

DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030201169     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00074-1     Document Type: Conference Paper

References (220)

1. 18F]fluorodeoxyglucose method for the measurement of the local cerebral glucose utilization in man. Circ. Res. 44, 127-137.
2. 18F]2-fluoro-2-deoxy-D-glucose: Validation of method. Ann. Neurol. 5, 371-388.
3. 3. Mazziotta J. C., Phelps M. E. and Kuhl D.E. (1981) Tomographic mapping of human cerebral metabolism: Normal unstimulated state. Neurology 31, 503-516.
4. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 32, 1323-1329.
5. 18F]Fluorodeoxyglucose and positron emission tomography in evaluation of radiation necrosis of the brain. Radiology 144, 885-889.
6. 6. Di Chiro G., Oldfield E., Bairamian D., Brooks R. A., Patronas N. J., Mansi L., Kornblith P. L., Smith B. H., Sank V. J. and Margolin R. A. (1985) In vivo glucose utilization of tumors of the brain stem and spinal cord. In: Positron Emission Tomography (Edited by Greitz T., Ingvar D. H. & Widen L.), pp. 351-361. Raven Press, New York.
7. 18F]fluorodeoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest. Radiol. 22, 360-371.
8. 8. Valk P. E., Budinger T. and Levin V. A. (1988) PET of malignant cerebral tumors after interstitial brachytherapy. J. Neurosurg. 69, 830-838.
9. 9. Patronas N.J., DiChiro G., Kufta C., Bairamian D., Kornblith P. L., Simon R. and Earson S. M. (1985) Prediction of survival in glioma patients by means of positron emission tomography. Neurosurgery 62, 816-822.
10. 10. Schelbert H. R., Phelps M. E., Hoffman E. J., Huang S., Selin C. E. and Kuhl D. E. (1979) Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission tomography. Am. J. Cardiol. 43, 209-221.
11. 11. Schelbert H. R. (1994) Metabolic imaging to assess myocardial viability. J. Nucl. Med. 35, 8S-14S.
12. 12. Schwaiger M. and Hicks R. (1991) The clinical role of metabolic imaging of the heart by positron emission tomography. J. Nucl. Med. 32, 565-578.
13. 13. Gould K. L. (1991) PET perfusion imaging and nuclear cardiology. J. Nucl. Med. 32, 579-606.
14. 14. Strauss L. G. and Conti P. S. (1991) The applications of PET in clinical oncology. J. Nucl. Med 32, 623-648.
15. 15. Wagner H. N. Jr. and Conti P. S. (1991) Advances in medical imaging for cancer diagnosis and treatment. Cancer 67, 1121-1128.
16. 16. Conti P. S., Keppler J. and Halls J. M. (1994) Positron emission tomography: A financial and operational analysis. Am. J. Roentg. 162, 1279-1286.
17. 17. Conti P. S. and Grafton S. T. (1994) Functional brain imaging using positron emission tomography: Applications in oncology and neurology. In: Functional Neuroimaging. (Edited by Kelley R. E.), pp. 19-50. Futura Publishing, Armonk, NY.
18. 18. Conn P. S. (1995) Introduction to imaging brain tumor metabolism with positron emission tomography. Cancer Invest. 13, 244-259.
19. 19. Cancer Facts and Figures (1994) American Cancer Society, Atlanta, GA.
20. 20. Bellmunt J., Moarales S., Navarro M. and Sole L. A. (1990) Ifosfamide and mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother. Pharmacol. 26, 81S-84S.
21. 21. Ghavamzadeh A. (1990) Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-FU. Cancer Chemotrier. Pharmacol. 26, 66S-68S.
22. 22. Hamsworth J. D., Andrew M. B., Johnson D. H. and Greco F. A. (1991) Mitoxantrone, fluorouracil, and high-dose leucovorin: An effective, well tolerated regimen for metastatic breast cancer. J. Clin. Oncol. 9, 1731-1735.
23. 18F]fluorodeoxyglucose and positron emission tomography. J. Comput. Assist. Tomogr. 13, 1097-1098.
24. 18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur. J. Nucl. Med. 15, 61-66.
25. 18F]-fluoro-2-deoxy-D-glucose. Radiology 179, 765-770.
26. 26. Tse N. Y, Hoh C. K., Hawkins R. A., Zinner M.J., Dahlbom M, Choi Y., Maddahi J., Brunicardi F. C., Phelps M. E. and Glaspy J. A. (1992) The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann. Surg. 216, 27-34.
27. 18F]-FDG PET. J. Nucl. Med. 33, 828.
28. 18F]-FDG-PET in breast tumors. Eur. J. Nucl. Med. 21, 749.
29. 29. Hoh C. K., Glaspy J. A., Choi Y., Tse N., Rege S., Nitzsche E. U., Dahlbom M., Maddahi J., Hoffman E. J., Phelps M. E. and Hawkins R. A. (1992) Quantitative dynamic and whole body PET FDG imaging of breast cancer. J. Nucl. Med. 33, 828P.
30. 30. Hoh C. K., Lee M. H., Rege S., Glaspy J., Bassett L. W. and Hawkins R. A. (1993) Whole-body PET with FDG: A potential complementary-imaging technique to mammography for detection of primary, recurrent, and metastatic breast carcinoma. Radiology 189, 148P.
31. 31. Hoh C. K, Hawkins R. A., Glaspy J. A., Choi Y., Tse M., Dahlbom M., Maddahi J. and Phelps M. E. (1994) Comparison of quantitative methods in FDG PET breast cancer studies. J. Nucl. Med. 35, 141P.
32. 32. Dehdashti F., Mortimer F. E., Griffeth L. K., McGuire A. H., Radford D. M., Fusselman M. J., Burney R. J., Bonaser T. A., Siegel B. A., Katzenellenbogen J. A. and Welch M. J. (1994) Positron tomographic assessment of breast lesions with FDG and FES. J. Nucl. Med. 35, 141P.
33. 33. Jacobs M., Mantil J., Peterson C., Reiling R., Glaser R., Satter M., Nickerson J., Dunigan K. and Brackney M. (1994) FDG PET in breast cancer. J. Nucl Med. 35, 142P.
34. 34. Avril N., Janicke F., Dose J., Ziegler S., Bense S., Hertz M., Langhammer H. R., Graeff H. and Schwaiger M. (1994) Imaging of breast tumors with FDG-PET in comparison with histology. Eur. J. Nucl. Med. 21, 749.
35. 35. Chaiken L., Rege S., Hoh C., Choi Y., Jabour B., Juillard G., Hawkins R. and Parker R. (1993) Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 27, 455-464.
36. 36. Wahl R. L., Zasadny K. R., Helvie M., Hutchins G. D., Weber B. and Cody R. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J. Clin. Oncol. 11, 2101-2111.
37. 37. Wahl R. L., Zasadny K. R., Cody R. and Helvie M. (1994) FDG accumulation in normal breasts declines with aging. J. Nucl. Med. 35, 142P.
38. 38. Conti P. S., Wdowczyk J. and Grafton S. T. (1995) Positron emission tomography (PET) imaging as a diagnostic adjunct in problematic breast cancer cases. 18th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-13.
39. 39. Alexander J. L., Gillespie P. J. and Edelstyn G. A. (1976) Serial bone scanning using technetium-99m diphosphonate in patients undergoing cyclical combination chemotherapy for advanced breast cancer. Clin. Nucl. Med. 1, 13-17.
40. 40. Arnstein N. B., Harbert J. C. and Byrne P. J. (1984) Efficacy of bone and liver scanning in breast cancer patients treated with adjuvant chemotherapy. Cancer 54, 2243-2247.
41. 41. Jacobson A. F., Shapiro C. L. and Kaplan W. D. (1995) Bone metastases in patients with breast cancer: Significance of scintigraphic patterns at presentation and follow-up. J. Nucl. Med. 34, 74P.
42. 42. Brandth S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E.J., Bast R. C., Gilbert C.J. and Oette D.H. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstruction after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318, 869-876.
43. 43. Antman K., Ayash L., Elias A., Wheeler C., Hunt M., Eder J. P., Teicher B. A., Critchlow J., Bibbo J. and Schnipper L. E. (1992) A Phase-II study of high-dose cyclophosphamide, thiotepa, and carbo-platin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol. 10, 102-110.
44. 44. Hillner B. E., Thomas J. S. and Desch C. E. (1992) Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. JAMA 267, 2055-2061.
45. 45. Uno K., Yoshikawa K., Imazeki K., Okada J., Minoshima S. and Anmizu N. (1992) FDG-PET evaluation of breast cancer: A diagnostic role for primary or metastatic and recurrent lesions. Radiology 185, 108P.
46. 46. Nieweg O. E., Kim E. E., Wong W-H., Broussard W. F., Singletary S. E., Hortobagyi G. N. and Tilbury R. S. (1993) Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71, 3920-3925.
47. 47. Crowe J. P., Adler L. P., Shenk R. R. and Sunshine J. (1994) Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings. Ann. Surg. Oncol. 1, 132-140.
48. 48. Jannson T., Westlin J. E., Ahlstrom H., Lilja A., Langstrom B. and Bergh J. (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation. J. Clin. Oncol 13, 1470-1477.
49. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur. J. Surg. Oncol. 21, 280-283.
50. 50. Avril N., Janicke F., Dose J., Bense S., Ziegler S., Zinke M., Laubenbacher C., Romer W., Herz M. and Schwaiger M. (1995) PET imaging of breast tumors: Munich experience. J. Nucl. Med. 36, 82P.
51. 51. Scheidhauer K., Scharl A., Pietrzyk U., Wagner R., Schomacker K., Theissen P. and Schicha H. (1995) Quantitation of [F-18]-FDG-PET in breast tumors. Eur. J. Nucl. Med. 22, 734.
52. 52. Dehdashti F., Mortimer J. E., Siegel B. A., Griffeth L. K., Bonasera T. J., Fusselman M.J., Deter D.D., Cutler P.D., Katzenellenbogen J. A. and Welch M. J. (1995) Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J. Nucl. Med. 36, 1766-1774.
53. 53. Pilipshen S., Heilweil M., Quan S. H., Sternberg S. S. and Enker W. E. (1984) Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 53, 1354-1362.
54. 54. Kelvin F. M. and Maglinte D. D. T. (1987) Colorectal carcinoma: A radiologic and clinical review. Radiology 164, 1-8.
55. 55. Wanebo H. J., Llaneras M., Martin T. and Kaiser D. (1989) Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg. Gynecol. Obstet. 169, 479-487.
56. 56. Moertel C. G., Fleming, T. R., MacDonald J. S., Haller D. G., Laurie J. A. and Tangen C. (1993) An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270, 943-947.
57. 57. Moss A.A. (1989) Imaging of colorectal carcinoma. Radiology 170, 308-310.
58. 58. Schlag P., Lehner B., Strauss L. G., Georgi P. and Herfarth C. (1989) Scar or recurrent rectal cancer. Arch. Surg. 124, 197-200.
59. 59. Strauss L. G., Clorius J. H., Schlag P., Lehner B., Kimming B., Engenhart R., Marin-Grez M., Helus F., Oberdorfer F., Schmidlin P. and van Kaick G. (1989) Recurrence of colorectal tumors: PET evaluation. Radiology 170, 329-332.
60. 60. Ito K., Kato T., Tadokoro M., Ishiguchi T., Oshima M., lshigaki T. and Sakuma S. (1992) Recurrent rectal cancer and scar: Differentiation with PET and MR imaging. Radiology 182, 549-552.
61. 18F-FDG. J. Nucl. Med. 34, 222P.
62. 62. Pounds T. R., Valk P. E., Haseman M. K., Myers R. W. and Lutrin C. L. (1995) Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer. J. Nucl. Med. 36, 57P.
63. 18F-FDG positron emission tomography (PET). J. Nucl. Med. 36, 107P.
64. 64. Falk P. M., Gupta N. C., Thorson A. G., Frick M. P., Boman B. M., Christensen M. A. and Blatchford G. J. (1994) Positron emission tomography for preoperative staging of colorectal carcinoma. Dis. Colon Rectum 37, 153-156.
65. 65. Haberkorn U., Strauss L. G., Dimitrakopoulou A., Engenhart R., Oberdorfer F., Ostertag H., Romahn J. and van Kaick G. (1991) PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J. Nucl. Med. 32, 1485-1490.
66. 66. Engenhart R., Kimmig B. N., Strauss L. G., Hover K. G., Romahn J., Haberkorn U., van Kaick G. and Wannenmacher M. (1992) Therapy monitoring of presacral recurrences after high-dose irradiation: Value of PET, CT, CEA and pain score. Strahlenther. Onkol. 168, 203-212.
67. 18F]-FDG and PET. Eur. J. Nucl. Med. 20, 977.
68. 18F] FDG whole body PET: Comparison with conventional diagnostic modalities. J. Nucl. Med. 36, 106P.
69. 69. Bares R., Dohmen B. M., Fass J., Kaiser H. J., Altehoefer C., Klever P., Schumpelick V. and Buell U. (1994) FDG-PET or CEA-immunoscintigraphy for detection of colorectal cancer? Results of a comparative study. Eur. J. Nucl. Med. 21, 759.
70. 70. Schiepers C., Penninckx F., De Vadder N., Merckx E., Mortelmans L., Bormans G., Marchal G., Filez L. and Aerts R. (1995) Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur. J. Surg. Oncol. 21, 517-522.
71. 71. Beets G., Penninck F., Shiepers C., Filez L. Mortelmans L., Kerremans R., Aerts R. and DeRoo M. (1994) Clinical value of whole-body positron emission tomography with (18F) fluorodeoxyglucose in recurrent colorectal cancer. Br. J. Surg. 81, 1666-1670.
72. 72. Ault G., Ceron O., Conti P. S., Simons A., Vukasin P., Anthone G., Ottega A. and Beart R. (1996) The use of PET scans in recurrent colorectal carcinoma. Annual Meeting Southern California Chapter American College of Surgeons. Santa Barbara, CA, January 26-28.
73. 73. Shields A. T., Graham M. M., Helton S., and Shields A.F. (1995) Utility of F-18 FDG PET in preoperative evaluation of patients with colon catcinoma metastatic to liver. J. Nucl. Med. 36, 106P.
74. 74. Fandi A., Altun M., Azli N., Armand J. P. and Cvitkovic E. (1994) Nasopharyngeal cancer: Epidemiology, staging and treatment. Semin. Oncol. 21, 382-397.
75. 75. Schuller D. E., McGuirt W. F., McCabe B. F. and Young D. (1980) The prospective significance of metastatic cervical lymph nodes. Laryngoscope 90, 557-570.
76. 76. van den Brekel M. W. M., Castelijns J. A., and Snow G. B. (1994) The role of modern imaging studies in the staging and therapy of head and neck neoplasms. Semin. Oncol. 21, 340-348.
77. 77. Horkijk G. J. and de Jong A. M. (1983) Synchronous and metachronous tumours in patients with head and neck cancer. J. Laryngol. Otol. 97, 619-621.
78. 78. Minn H., Joensuu H., Ahonen A. and Klemi P. (1988) Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Cancer 61, 1776-1781.
79. 79. Minn H., Clavo A. C., Grenman R. and Wahl R. L. (1995) In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J. Nucl. Med. 36, 252-258.
80. 80. Haberkorn U., Strauss L. G., Reisser C. H., Haag D., Dimitrakopoulou A., Ziegler S., Oberdorfer F., Rudat V. and van Kaick G. (1991) Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J. Nucl. Med. 32, 1548-1555.
81. 81. Bailet J. W., Abemayor E., Jabour B. A., Hawkins R. A., Ho C. and Ward P. H. (1992) Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 102, 281-288.
82. 82. Braams J. W., Pruim J., Freling N. J. M., Nikkels P. G. J., Roodenburg J. L. N., Boering G., Vaalburg W. and Vermey A. (1995) Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J. Nucl. Med. 36, 211-216.
83. 18F]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 186, 27-35.
84. 84. Chaiken L., Rebe S., Hoh C., Choi Y., Jabour B., Juillard G., Hawkins R. and Parker R. (1993) Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 27, 455-464.
85. 85. Rege S., Maass A., Chaiken L., Hoh C. K., Choi Y., Lufkin R., Anzai Y., Juillard G., Maddahi J. and Phelps M. E. (1994) Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 73, 3047-3058.
86. 86. Minn H., Paul R. and Ahonen A. (1988) Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J. Nucl. Med. 29, 1521-1525.
87. 87. Haberkorn U., Strauss L. G., Dimitrakopoulou A., Seiffert E., Oberdorfer F., Ziegler S., Reisser C., Doll J., Helus F. and van Kaick G. (1993) Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med. 34, 12-17.
88. 88. Rege S. D., Chaiken L., Hoh C. K., Choi Y., Lufkin R., Anzai Y., Juillard G., Maddahi J., Phelps M. E. and Hawkins R. A. (1993) Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: Quantitation with PET. Radiology 189, 807-812.
89. 89. Reisser C. H., Haberkorn U. and Strauss L. G. (1993) The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J. Otolaryngol. 22, 231-238.
90. 90. Reisser C., Haberkorn U., Dimitrakopoulou-Strauss A., Seifert E. and Strauss L. G. (1995) Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch. Otolaryngol. Head Neck Surg. 121, 272-276.
91. 91. Greven K. M., Williams D. W., Keyes J. W., McGuirt W. F., Watson N. E., Randall M. E., Raben M., Geisinger K. R. and Cappellari J. O. (1994a) Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74, 1355-1359.
92. 92. Greven K. M., Williams D. W., Keyes J. W., McGuirt W. F., Harkness B. A., Watson N. E., Raben M., Frazier L. C., Geisinger K. R. and Cappellari J. O. (1994b) Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int. J. Radiat. Oncol. Biol. Phys. 29, 841-845.
93. 93. Mancuso A. A., Drane W. E. and Mukherji S. K. (1994) The promise of FDG in diagnosis and surveillance of head and neck cancer. Cancer 74, 1193-1195.
94. 94. Lindholm P., Leskinen-Kallio S., Minn H., Bergman J., Haaparanta M., Lehikoinen P., Nagren K., Ruotsalainen U., Teras M. and Joensuu H. (1993) Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J. Nucl. Med. 34, 1711-1716.
95. 18F] FDG PET, MRI, and endoscopy for preoperative staging of squamous cell carcinomas (SCC) of the head and neck. Eur. J. Nucl. Med. 21, 858.
96. 96. Mukherji S. K., Drane W. E., Tart R. P., Landau S. and Mancuso A. A. (1994) Comparison of thallium-201 and F-18 FDG SPECT upcake in squamous cell carcinoma of the head and neck. Am. J. Neuroradiol 15, 1837-1842.
97. 97. Slosman D. O., Benchaou M., Rufenact D., Widmann J. J., Donath A. and Lehmann W. (1993) F-18 FDG PET: Use of a rotating camera in preoperative staging of head and neck cancer. Radiology 189, 200P-201P.
98. 98. Zeitouni A. G., Yamamoto Y. L., Black M. and Gjedde A. (1994) Functional imaging of head and neck tumours using positron emission tomography. J. Otolaryngol. 23, 77-80.
99. 99. Gurney J. W. (1993) Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis: Part 1. Theory. Radiology 186, 405-413.
100. 100. Zerhouni E. A., Stitik F. P., Siegelman S. S., Naidich D. P., Sagel S. S., Proto A. V., Muhm J. R., Walsh J. W., Martinez C. R. and Heelan R. T. (1986) Computed tomography of the pulmonary nodule: A national cooperative study. Radiology 160, 319-327.
101. 101. Lillington G. A. (1988) Systemic diagnostic approach to pulmonary nodules. In: Pulmonary Diseases and Disorders (Edited by Fishman A. P.), 2nd edn. McGraw-Hill, New York.
102. 102. Mountain C. F. (1977) Assessment of the role of surgery for control of lung cancer. Ann. Thorac. Surg. 24, 365-371.
103. 103. Webb W. R., Gatsonis C., Zerhouni E. A., Heelan R. T., Glazer G. M., Francis I. R. and McNeil B. J. (1991) CT and MR imaging in staging non-small-cell bronchogenic carcinoma: Report of the Radiologic Diagnostic Oncology Group. Radiology 178, 705-713.
104. 104. Pearson F. G., Delarue N. C., Ilves R., Todd T. R. and Cooper J. D. (1982) Significance of positive mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J. Thorac. Cardiovasc. Surg. 83, 1-11.
105. 11C]-glucose for diagnosis of lung cancer. Proceedings of the Third World Congress of Nuclear Medicine and Bioiogy, pp. 2080-2082.
106. 18F]-Deoxy-D-glucose positron emission tomography of human lung tumors. Cyclotron and Radioisotope Center Annual Report, pp. 264-269.
107. 107. Nolop K. B., Rhodes C. G., Burdin L. H., Beaney R. P., Krausz T., Jones T. and Hughes J. M. B. (1987) Glucose utilization in vivo by human pulmonary neoplasms. Cancer 60, 2682-2689.
108. 18F] fluorodeoxyglucose PET. J. Nucl. Med. 33, 828P.
109. 109. Knopp M. V., Bischoff H., Ostertag H., Helus F., Doll J., Bauer H., Vogt-Moykopf I., Lorenz, W. and van Kaick G. (1993) Clinical application of FDG-PET for staging of bronchogenic carcinoma. J. Nucl. Med. 34, 21P.
110. 110. Valk P. E., Pounds T. R., Hopkins D. M., Haseman M. K., Hofer G. A. and Greiss H. B. (1995) Staging lung cancer by whole-body PET-FDG imaging. J. Nucl. Med. 36, 95P.
111. 111. Valk P.E., Pounds T. R., Hopkins D.M., Haseman M. K., Hofer G. A., Greiss H. B., Myers R. W. and Lutrin C. L. (1995) Staging lung cancer by PET imaging. Ann. Thorac. Surg. 60, 1573-1582.
112. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344, 1265-1266.
113. 113. Wahl R. L., Quint L. E., Greenough R. L., Meyer C. R., White R. L. and Orringer M. B. (1994) Staging of mediastinal non-small-cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation. Radiology 191, 371-377.
114. 114. Shelton D. K., Pounds T. R., Lau D., Sutter C. W., Ivanovic M. and Valk P.E. (1995) Diagnosis of bone metastasis in lung cancer by whole-body PET-FDG imaging: Comparison to conventional skeletal scintigraphy. J. Nucl. Med. 36, 200P.
115. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 19, 1005-1010.
116. 116. Knopp M. V., Bischoff H., Rimac A., Doll J., Oberdorfer F., Lorenz W. J. and van Kaick G. (1994) Clinical utility of positron emission tomography with FDG for chemotherapy response monitoring-A correlative study of patients with small cell lung cancer. J. Nucl. Med. 35, 75P.
117. 18F]-2-deoxy-D-glucose. Radiology 191, 379-382.
118. 118. Kubota K., Matsuzawa T., Fujiwara T., Ito M., Hatazawa J., Ishiwata K., Iwata R. and Ido T. (1990) Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J. Nucl. Med. 31, 1927-1932.
119. 119. Dehdashti F., Griffeth L. K., McGuire A. H., Goodenberger D.M., Perry D. J. and Siegel B. A. (1992) FDG-PET evaluation of suspicious pulmonary and mediastinal masses. J. Nucl. Med. 32, 961P.
120. 18F] FDG PET in the monitoring and management of response to lung cancer therapy. Radiology 185, 186P.
121. 121. Strauss L. G., Dimitrakopoulou A. D., Haberkorn U., Manke H., Oberdorfer F. and Wolber G. (1992) PET follow-up studies to evaluate tumor perfusion and metabolism in patients with small cell carcinoma of the lung. Radiology 5, 139P.
122. 18F] fluorodeoxyglucose PET scanning. Radiology 188, 487-490.
123. 123. Slosman D.O., Spiliopoulos A., Couson F., Nicod L., Louis O., Lemoine R., Donath A. and Junod A. F. (1993) Satellite PET and lung cancer: A prospective study in surgical patients. Nucl. Med. Comm. 14, 955-961.
124. 124. Rege S. D., Hoh C. K., Glaspy J. A., Aberle D. R., Dahlbom M., Razavi M. K., Phelps M. E. and Hawkins R. A. (1993) Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodexyglucose. Cancer 72, 82-90.
125. 125. Khonsary S. A., Mandelkern M. A., Brown C. V., Blahd W. H., Farahi J. B., Ropchan J. R., Quinones N., Ribe J., Sazon D. A., Santiago S. and Williams A.J. (1993) PET-FDG scanning in pulmonary mass lesions. Clin. Nucl. Med. 18, 922.
126. 18F]-FDG positron emission tomography with surgical pathology. Eur. J. Nucl. Med. 21, 62S.
127. 127. Gupta N. C., Dewan N., Maloof J. and Gunel E. (1994) Superiority of FDG PET imaging in predicting the probability for malignancy in patients with indeterminate solitary pulmonary nodules. Radiology 193, 131P.
128. 128. Weber W., Romer W., Ziegler S., Schad D., Herz M., Prauer H. and Schwaiger M. (1995) Clinical value of F-18-FDG PET in solitary pulmonary nodules. Eur. J. Nucl. Med. 22, 775.
129. 18F-fluoro-deoxyglucose in the assessment of solitary pulmonary nodules. Eur. J. Nucl. Med. 22, 775.
130. 18F]-fluoro-2-deoxy-D-glucose for preoperative staging of lung cancer: Influence on patients' management. Eur. J. Nucl. Med. 22, 775.
131. 131. Duhaylongsod F. G., Lowe V. J., Patz E. F., Vaughn A. L., Coleman R. E. and Wolfe W. G. (1995) Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J. Thorac. Cardiovasc. Surg. 110, 130-140.
132. 132. Hubner K. F., Buonocore E., Singh S. K., Gould H. R. and Cotten D. W. (1995) Characterization of chest masses by FDG positron emission tomography. Clin. Nucl. Med. 20, 293-298.
133. 133. Grimmel S., Storck M., Henrich M. M., Kocher F., Sunder-Plassman E. and Reske S. N. (1993) Diagnostic value of 18-F-FDG-PET in patients with lung cancer and lymph node metastases. Eur. J. Nucl. Med. 20, 819.
134. 134. Buchpiguel C. A., Tse K., Alavi A., Alavi J. B., Smith R. J., Meehan D. and Riggin S. L. (1994) Use of quantitative FDG-PET whole-body imaging in staging lung cancer. A comparison with CT. Eur. J. Nucl. Med. 21, S61.
135. 135. Patz E. F., Lowe V. J. and Goodman P. C. (1994) Bronchogenic carcinoma: Staging of disease in the hilum and mediastinum by using FDG PET with CT and surgical correlation. Radiology 193, 257P.
136. 136. Sasaki M., Ichiya Y., Kuwabara Y., Akashi Y., Yoshida T., Fukumura T., Murayama S. and Masuda K. (1994) The usefulness of FDG-PET for the detection of mediastinal lymph node metastases in patients with non-small-cell lung cancer: A comparative study with x-ray CT. Eur. J. Nucl. Med. 21, 189S.
137. 18F]fluorodeoxyglucose. Ann. Thorac. Surg. 58, 698-703.
138. 138. Bury Th., Paulus P., Benoit Th., Corhay J. L., Radermecker M. F. and Rigo P. (1995) Positron emission tomography versus computed tomography in the staging of mediastinal non-small-cell lung cancer. Eur. J. Nucl. Med. 22, 846.
139. 139. Nadar I., Hoh C., Figlin R. A., Holmes C. E., Waters P. F., Gambhir S. S., Phelps M. E. and Maddahi J. (1995) Cost-effective staging of non-small-cell lung carcinoma by whole-body PET FDG imaging. J. Nucl. Med. 36, 57P.
140. 140. Inoue T., Kim E. E., Komaki R., Wong F. C. L., Bassa P., Wong W-H., Yang D. J., Endo K. and Podoloff D. A. (1995) Detecting recurrent or residual lung cancer with FDG-PET. J. Nucl. Med. 36, 788-793.
141. 141. Paul R. (1987) Comparison of fluorine-18 2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J. Nucl. Med. 28, 288-292.
142. 142. Okada J., Yoshikawa K., Imazeki K., Minoshima S., Uno K., Itami J., Kuyama J., Maruno H. and Arimizu N. (1991) The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J. Nucl. Med. 32, 686-691.
143. 143. Okada J., Yoshikawa K., Itami M. Imaseki K., Uno K., Itami J., Kauama J., Mikata A. and Arimizu N. (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J. Nucl. Med. 33, 325-329.
144. 144. Leskinen-Kallio S., Ruotsalainen U., Nagren K., Teras M. and Joensuu H. (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J. Nucl. Med. 32, 1211-1218.
145. 145. Hoekstra O. S., Ossenkoppele G. J., Golding R., van Lingen A., Visser G. W. M., Teule G. J. J. and Huijgens P.C. (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med. 34, 1706-1710.
146. 18F]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 190, 111-116.
147. 18F]-FDG-PET for staging of malignant lymphomas. Eur. J. Nucl. Med. 21, 727.
148. 148. Schonberger J. A., Kocher F., Glatz S., Bangerter M., Frickhofen N., Heimpel H. and Reske S. N. (1995) Whole-body 18-FDG-PET for staging and therapy-control of malignant lymphomas. J. Nucl. Med. 36, 224P.
149. 149. Valk P. E., Pounds T. R., Wolkov H. B., Leibenhaut M. L., Haseman M. K., Myers R-W. and Lutrin C. L. (1995) PET-FDG whole-body imaging in staging Hodgkin's disease: Comparison to conventional imaging. J. Nucl. Med. 36, 199P.
150. 18F] fluorodeoxyglucose (FDG) PET to assess local affects of radiation or chemotherapy in patients with malignant lymphoma. J. Nucl. Med. 32, 918.
151. 151. Dimitrakopoulou-Strauss A., Strauss L. G., Goldschmidt H., Lorenz W. J., Maier-Borst W. and van Kaick G. (1994) Evaluation of tumor metabolism and multi-drug resistance in patients with treated malignant lymphomas. Eur. J. Nucl. Med. 21, 727.
152. 18F]-deoxyglucose (FDG) and Tc-99m-Sestamibi in patients with recurrent malignant lymphoma. J. Nucl. Med. 36, 216P.
153. 153. Huffman J. M., Waskin H. A., Schifter T., Hanson M. W., Gray L., Rosenfeld S. and Coleman R. E. (1993) FDG-PET in differentiating lymphoma from non-malignant central nervous system lesions in patients with AIDS. J. Nucl. Med. 34, 567-575.
154. 154. Henrich M. M., Bangerter M., Grimmel S., Frickhofen N., Heimpel H. and Reske S. N. (1993) FDG-PET for staging patients with malignant lymphoma. Eur. J. Nucl. Med. 20, 977.
155. 155. Zanzi I., Vinciguerra V., Schulman P., Robeson W., Babchyck B., Kroop S., Chaly T., Dahl J. R. and Margouleff D. (1993) Evaluation of malignant lymphoma with FDG/PET studies. Eur. J. Nucl. Med. 20, 977.
156. 156. Rodriguez M., Rehn S., Ahlstrom H., Sundstrom C. and Blimelius B. (1995) Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J. Nucl. Med. 36, 1790-1796.
157. 157. Skolnick A. A. (1991) Melanoma epidemic yields grim statistics. JAMA 265, 3217-3218.
158. 158. Gumport S. L. and Meyer H. W. (1959) Treatment of 126 cases of malignant melanoma: Long-term results. Ann. Surg. 150, 989-992.
159. 159. Conti P. S., Sordillo P. P., Sordillo E. M. and Schmall B. (1986) Tumor localization of the metabolically trapped radiolabeled substrates 2-deoxy-D-glucose and aminocyclopentanecarboxylic acid in human melanoma heterotransplants. Am. J. Clin. Oncol. 9, 537-540.
160. 160. Gritters L. S., Francis I. R., Azsadny K. R. and Wahl R. L. (1993) Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J. Nucl. Med. 34, 1420-1427.
161. 161. Kirgan D., Guenther J., Bhattathiry M., Glass E., Hoh, C., Maddahi H., Blahd W. and Morton D. (1994) The importance of whole-body PET scans on the management of metastatic malignant melanoma. Proc. Amer. Soc. Clin. Oncol. 13, 396.
162. 162. Yao W. J., Hoh C. K., Glaspy J. A., Asgarzadie F., Kirgan D., Morton D., Bhattathiry M., Glass E., Phelps M. and Maddahi J. (1994) Whole-body FDG PET imaging for staging of malignant melanoma: Is it cost effective?J. Nucl. Med. 35, 8P.
163. 18F]FDG. Eur. J. Nucl. Med. 21, 799.
164. 18F]-fluoro-2-deoxy-D-glucose. Radiology 195, 705-709.
165. 165. Steinert H., Huch-Boni R. A., Boni R., Buck A., Berthold T., Burg G. and von Schulthess G. K. (1995) Malignant melanoma: Staging with whole-body FDG-PET. J. Nucl. Med. 36, 191P.
166. 166. Steinert H., Huch-Boni R. A., Boni R., Buck A., Burger C., Berthold T., Burg G. and von Schulthess G. K. (1995) Metastatic melanoma: Staging with whole body FDG-PET and first experience with image fusion of PET and spiral CT. Eur. J. Nucl. Med. 22, 754P.
167. 167. Pounds T. R., Valk P.E., Haseman M. K., Myers R. W. and Lutrin C. L. (1995) Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: Comparison to CT. J. Nucl. Med. 36, 116P.
168. 168. Argenyi E. E., Urdaneta L. F., Whitaker D. C., Uygur G. S., Ponto L. L. B., Hichwa R. D., Watkins G. L. and Kirchner P. T. (1995) Clinical utility of F-18 FDG and PET imaging in detecting metastatic melanoma. J. Nucl Med. 36, 193P.
169. 169. Macfarlane D. J., Sondak V. and Wahl R. L. (1995) Initial prospective evaluation of FDG-PET in staging regional lymph nodes in patients with cutaneous malignant melanoma. J. Nucl. Med. 36, 116P.
170. 170. Strauss L. G., Tilgen W., Dimitrakopoulou A. D., Haverkorn U., Oberdorfer F. and Ostertag H. (1992) FDG in patients with metastatic melanoma before and after therapy. Radiology 185, 108P.
171. 171. Kern K. A., Brunetti A., Norton J. A., Chang A. E., Malawer M., Lack E., Finn R. D., Rosenberg S.A. and Larson S. M. (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med. 29, 181-186.
172. 18F] FDG. J. Comput. Assist. Tomogr. 14, 960-962.
173. 173. Adler L. P., Blair H. F., Makley J. T., Williams R. P., Joyce M. J., Leisure G., Al-Kaisi N. and Miraldi F. (1991) Noninvasive grading of musculoskeletal tumors using PET. J. Nucl. Med. 32, 1508-1512.
174. 174. Griffeth L. K., Dehdashti F., McGuire A. H., McGuire D. J., Perry D. J., Moerlein S. M. and Siegel B. A. (1992) PET evaluation of softtissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 182, 185-194.
175. 175. Korkmaz M., Kim E. E., Wong F., Haynie T., Wong W. H., Tilbury R. and Benjamin R. (1993) FDG and methionine PET in differentiation of recurrent or residual musculoskeletal sarcomas from post-therapy changes. J. Nucl. Med. 34, 33P.
176. 176. Nieweg O., Pruim J., Willemsen A. T. M., Hoekstra H. J., Paans A. M. J., Vaalburg W., Molenaar W. M., Oldhoff J. and Koops H. S. (1993) Detection and grading of primary and recurrent soft tissue sarcomas with PET and FDG. J. Nucl. Med. 34, 219P.
177. 177. Kim E. E., Garcia J. R., Wong F. C., Podoloff D. A., Nam K., Wong W-H. and Tilbury R. S. (1994) Evaluation of residual or recurrent musculoskeletal sarcomas using F-18-fluorodeoxyglucose (FDG) PET and Tc-99m-sestamibi (MIBI) SPECT. Am. J. Roent. 162, 279.
178. 178. Jacobs I. and Bast R. C. Jr. (1989) The CA-125 tumor-associated antigen: A review of the literature. Hum. Reprod. 4, 1-12.
179. 179. Einhorn N., Bast R. C., Knapp R. C., Tjernberg B. and Zurawski V. R. (1986) Preoperative evaluation of scrum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet. Gynecol. 67, 414-416.
180. 180. Friedman J. B. and Weiss N. S. (1990) Second thoughts about second-look laparotomy in advanced ovarian cancer. N. Engl. J. Med. 322, 1079-1082.
181. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol. Oncol. 51, 175-181.
182. 182. Casey M. J., Gupta N. C. and Muths C. K. (1994) Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol. Oncol. 53, 331-338.
183. 18F]FDG). Gynecol. Oncol. 51, 197-204.
184. 184. Hubner K. F., Smith G. T., Hunter K., Stephens T. S., Gould H. R., McDonald T. W. and Buonocore E. (1994) Assessment of primary and recurrent cancer of the ovary using F-18-FDG PET. 6th Annual Meeting of the Institute for Clinical PET, Washington, DC, October 13-16.
185. 185. van der Burg M. E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., Lacave A.J., Nardi M., Renard J. and Pecorelli S. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332, 629-634.
186. 186. Muderspach L., Muggia F. M. and Conti P. S. (1996) Second-look for Stage III epithelial ovarian cancer: Rationale and current issues. Cancer Treat. Rev. (in press).
187. 187. Avril N., Janicke F., Dose J., Ziegler S., Wolf I., Hertz M., Bense S., Graeff H. and Schwaiger M. (1994) Evaluation of FDG-PET in patients with pelvic masses suspicious for primary or recurrent ovarian cancer. Eur. J. Nucl. Med. 21, 853.
188. 188. Wahl R. L., Hutching G. and Roberts J. (1991) FDG PET Imaging of ovarian cancer: Initial evaluation in patients. J. Nucl. Med. 32, 982.
189. 189. Boland G. W., Goldberg M. A., Goff B., Dixon J. T., Fischman A. J. and Mueller P. R. (1993) PET for peritoneal carcinomatosis; Correlation with surgery and CT. Radiology 189, 147P.
190. 190. Hubner K. F., Smith G. T., Stephens T. S., Singh R. P., Gould H. R., McDonald T. W. and Buonocore E. (1995) Detecting recurrent ovarian cancer using F-18-FDG PET. J. Nucl. Med. 36, 106P.
191. 191. Zanzi I., Robeson W., Vinciguerra V., Kroop S. Chaly T., Schulman P., Dahl R., Goldman I. S., Allen S. L. and Margouleff D. (1990) Positron tomography (PET) imaging in patients with carcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 9, 434A.
192. 192. Klever P., Bares R., Fass J., Bull U. and Schumpelick V. (1992) PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 340, 1158-1159.
193. 193. Bares R., Klever P., Hambuechen U., Hellwig D., Fass J., Buell U. and Schumpelick V. (1993) Positron emission tomography (PET) with fluorine-18-labeled deoxyglucose (FDG) for detection of pancreatic cancer (PC): Comparison with CT, ultrasonography (US), and ERCP. J. Nucl. Med. 34, 98P.
194. 194. Higashi T., Tamaki N., Torizuka T., Inokuma T., Honda T., Magata Y., Yonekura Y., Ohshio G., Hosotani R., Imamura M. and Konishi J. (1995) Differentiation of malignant from benign pancreatic tumors by FDG-PET: Comparison with CT, US, and endoscopic ultrasonography. J. Nucl. Med. 36, 224P.
195. 195. Inokuma T., Tamaki N., Torizuka T., Magata Y., Fujii M., Yonekura Y., Kajiyama T., Ohshio G., Imamura M. and Konishi J. (1995) Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US. Radiology 195, 345-352.
196. 196. Stollfuss J. C., Schonberger J. A., Fries H., Beger H. G. and Reske S. N. (1994) Improved diagnosis of pancreatic carcinoma with FDG-PET compared to CT in non-invasive imaging modalities. Eur. J. Nucl. Med. 22, 759P.
197. 18F]-FDG PET, CT and ERCP. J. Nucl. Med. 36, 223-224.
198. 198. Stollfuss J. C., Glatting G., Friess H., Kocher F., Beger H. G. and Reske S. N. (1995) 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 195, 339-344.
199. 199. Stollfuss J., Kocher F., Glatting G., Glatz S. and Reske S. N. (1995) 18-FDG PET, CT and ERCP in the diagnosis of pancreatic cancer. Eur. J. Nucl. Med. 22, 826P.
200. 200. Bares R., Klever P., Hauptmann S., Hellwig D., Fass J., Cremerius U., Schumpelick V., Mittermayer C. and Bull U. (1994) F-18 Fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192, 79-86.
201. 201. Bares R., Dohmen B. M., Klever P., Hauptmann S., Fass J., Schumpelick V., Mittermayer C. and Buell U. (1995) FDG-PET for preoperative assessment of pancreatic masses: Results of a prospective study. J. Nucl. Med. 36, 224P.
202. 202. Bares R., Dohmen B. M., Klever P., Hauptmann S., Fass J., Mittermayer C., Schumpelick V. and Buell U. (1995) Clinical impact of FDG-PET for the diagnosis of pancreatic cancer. EANM 22, 826P.
203. 203. Inokuma T., Tamaki N., Torizuka T., Fujita T., Magata Y., Yonekura Y., Ohshio G., Imamura M. and Konishi J. (1995) Value of fluorine-18 fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J. Nucl. Med. 36, 229-235.
204. 204. Vander J. V., Gaston E. A., and Dawber T. R. (1968) The significance of nontoxic thyroid nodules: Final report of a 15-year study of the incidence of thyroid malignancy. Ann. Int. Med. 69, 537-540.
205. 205. Gharib H. and Goellner J. R. (1993) Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann. Int. Med. 118, 282-289.
206. 206. Joensuu H. and Ahonen A. (1987) Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J. Nucl. Med. 28, 910-914.
207. 18F-Fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur. J. Nucl. Med. 13, 502-506.
208. 208. Blahd W. H., Khonsary S. A., Brown C. V., Mandelkern M. A., Ropchan J. R., Farahi J. B., Quinones N., Ribe J. Y. and Coyle J. J. (1993) Thyroid cancer imaging with PET FDG. J. Nucl. Med. 34, 12P.
209. 18F]-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy. J. Clin. Endocrinol. Metab. 77, 1090-1094.
210. 210. Conti P. S., Wdowozyk J., Grafton S. T., Bacqui F., Singer P. A. and Nickoloff J. T. (1994) Improved detection of locally recurrent and metastatic thyroid cancer in patients with persistently elevated thyroglobulin using FDG PET scanning. Eur. J. Nucl. Med. 21, S10.
211. 18F]FDG and I-131 scintigraphy in patients with thyroid carcinoma. Eur. J. Nucl. Med. 21, 780P.
212. 18F-FDG PET in primary and metastatic thyroid cancer. J. Nucl. Med. 36, 196P.
213. 18F] PET imaging in I-131 therapy. J. Nucl. Med. 36, 197P.
214. 18F] FDG and T1-201 for detection of recurrent metastatic differentiated thyroid cancers. J. Nucl. Med. 36, 203P.
215. 215. Hanke J. P., Feine U., Lietzenmayor R., Wohrle H. and Muller-Schauenburg W. (1995) Whole-body 18-F-fluorodeoxyglucose PET in 24 patients with differentiated thyroid cancer - flip-flop behavior in uptake patterns of FDG and I-131. Eur. J. Nucl. Med. 23, 769P.
216. 216. Adler L. P. and Bloom A. D. (1993) Positron emission tomography of thyroid masses. Thyroid 3, 195-200.
217. 217. Bloom A. E., Adler L. P. and Shuck J. M. (1993) Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114, 728-735.
218. 218. Conti P. S., Durski J. M., Grafton S. T. and Singer P. A. (1996) PET imaging of locally recurrent and metastatic thyroid cancer. J. Nucl. Med. 37, 135P.
219. 219. Ramanna L., Waxman A. and Braunstein G. (1991) Thallium-201 scintigraphy in differentiated thyroid cancer: Comparison with radio-iodine scintigraphy and serum thyroglobulin determinations. J. Nucl. Med. 32, 441-446.
220. 99mTc-MIBI in the follow-up of differentiated thyroid cancer. Nuklearmedizin 30, 115-124.